As of 2026-05-20, the EV/EBITDA ratio of Castle Biosciences Inc (CSTL) is -28.40. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CSTL's latest enterprise value is 529.69 mil USD. CSTL's TTM EBITDA according to its financial statements is -18.65 mil USD. Dividing these 2 quantities gives us the above CSTL EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.5x - 10.1x | 9.2x |
| Forward P/E multiples | 9.3x - 10.7x | 9.8x |
| Fair Price | (4.01) - (4.47) | (4.13) |
| Upside | -120.9% - -123.3% | -121.5% |
| Date | EV/EBITDA |
| 2026-05-19 | -28.40 |
| 2026-05-18 | -28.60 |
| 2026-05-15 | -28.29 |
| 2026-05-14 | -27.88 |
| 2026-05-13 | -26.70 |
| 2026-05-12 | -27.48 |
| 2026-05-11 | -28.14 |
| 2026-05-08 | -29.43 |
| 2026-05-07 | -28.47 |
| 2026-05-06 | -37.42 |
| 2026-05-05 | -37.18 |
| 2026-05-04 | -38.67 |
| 2026-05-01 | -37.52 |
| 2026-04-30 | -37.00 |
| 2026-04-29 | -36.59 |
| 2026-04-28 | -37.32 |
| 2026-04-27 | -37.80 |
| 2026-04-24 | -36.95 |
| 2026-04-23 | -35.70 |
| 2026-04-22 | -37.99 |
| 2026-04-21 | -37.15 |
| 2026-04-20 | -38.09 |
| 2026-04-17 | -37.91 |
| 2026-04-16 | -37.11 |
| 2026-04-15 | -37.21 |
| 2026-04-14 | -36.80 |
| 2026-04-13 | -35.44 |
| 2026-04-10 | -34.79 |
| 2026-04-09 | -35.28 |
| 2026-04-08 | -38.14 |
| 2026-04-07 | -37.55 |
| 2026-04-06 | -37.39 |
| 2026-04-02 | -37.57 |
| 2026-04-01 | -37.91 |
| 2026-03-31 | -37.10 |
| 2026-03-30 | -35.47 |
| 2026-03-27 | -35.44 |
| 2026-03-26 | -37.34 |
| 2026-03-25 | -38.27 |
| 2026-03-24 | -38.40 |
| 2026-03-23 | -39.05 |
| 2026-03-20 | -37.83 |
| 2026-03-19 | -38.97 |
| 2026-03-18 | -38.83 |
| 2026-03-17 | -39.29 |
| 2026-03-16 | -39.18 |
| 2026-03-13 | -38.74 |
| 2026-03-12 | -38.35 |
| 2026-03-11 | -39.66 |
| 2026-03-10 | -40.43 |